Lfcr.O

Lifecore Biomedical Inc exhibits a highly leveraged capital structure characterized by significant debt burden relative to equity. The company reports total liabilities of $191.9 million against total equity of $1.3 million, resulting in a debt-to-equity ratio of 97.63. Long-term debt stands at $130.4 million, while cash and equivalents are limited to $8.3 million, creating a net cash position that is negative after subtracting total debt. The current ratio is not explicitly provided, but the liquidity risk is assessed as medium, reflecting the tight balance between operating cash flow of -$0.2 million and substantial debt obligations. The market capitalization is $160.0 million, implying an enterprise value that includes the heavy debt load, with an EV/Revenue multiple of 2.22.

Profitability metrics indicate significant operational challenges, with the company reporting a net loss of $38.7 million on revenue of $128.9 million. The operating income is negative at -$17.2 million, and the gross profit is $40.3 million, suggesting that operating expenses significantly outpace gross margins. Return on equity is reported as 5.83, and return on assets is 0.03, though these figures are distorted by the negative net income and low equity base. The price-to-earnings ratio is listed as 20.54, which is anomalous given the net loss, likely reflecting a calculation artifact or forward-looking estimate not supported by current trailing earnings. The EV/EBITDA is negative at -57.56, consistent with the operating losses.

Segment and geographic revenue breakdowns are not provided in the available data, preventing a detailed analysis of revenue concentration or regional exposure. The company’s activity is broadly classified as Life Sciences Tools & Services, but specific product lines or customer concentrations are not disclosed in the current snapshot. Without segment data, the assessment of diversification risks remains limited to the overall financial performance.

Growth trajectory analysis is constrained by the absence of historical period data in the input. The current revenue of $128.9 million serves as the baseline, but year-over-year or quarter-over-quarter trends cannot be calculated from the provided financial snapshot. The lack of historical context limits the ability to assess whether the current revenue level represents expansion, contraction, or stability relative to prior periods.

Risk factors are dominated by liquidity and solvency concerns. The key flag indicates that net cash is negative after subtracting total debt, highlighting the company’s reliance on external financing or asset liquidation to meet obligations. Liquidity risk is rated as medium, while dilution risk is assessed as low, suggesting that equity issuance is not currently a primary method for addressing the debt burden. The high debt-to-equity ratio of 97.63 amplifies financial risk, making the company sensitive to interest rate changes and refinancing conditions.

Recent events include analyst coverage updates with a mean price target of $6.83 and a median target of $6.50, indicating a potential upside from the current market price of $4.32. The mean recommendation is 2.00, with two strong buys, one buy, and two holds, suggesting a cautiously optimistic view among analysts. News observations indicate reconciler activities related to coverage closure and analysis job processing, but no specific corporate actions or strategic announcements are detailed in the recent news feed.

Revenue $23.2M, −28,8% YoY; Operating income −138,5% YoY.

• ▍Revenue $23.2M, −28,8% YoY
• ▍Operating income −138,5% YoY
• ▍Net income −128,0% YoY
• ▍Free cash flow −61,0% YoY
• ▍Net margin -64.6%

Revenue $75.5M, −41,1% YoY; Operating income +91,7% YoY.

• ▍Revenue $75.5M, −41,1% YoY
• ▍Operating income +91,7% YoY
• ▍Net income −249,5% YoY
• ▍Net margin -23.8%